{"entity":{"id":"ifngr1","kind":"target","name":"IFNGR1","aka":["interferon gamma receptor 1","Interferon gamma receptor 1","CD119","IFNGR"],"tldr":"IFNGR1 (Interferon gamma receptor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","summary":"Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Associates with transmembrane accessory factor IFNGR2 to form a functional receptor. Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signalling components JAK1 and JAK2.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Ipilimumab.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:5439","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5439"},{"label":"UniProt P15260","url":"https://www.uniprot.org/uniprotkb/P15260/entry"},{"label":"NCBI Gene 3459","url":"https://www.ncbi.nlm.nih.gov/gene/3459"},{"label":"Ensembl ENSG00000027697","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000027697"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"IFNGR1","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:5439","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5439","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P15260","url":"https://www.uniprot.org/uniprotkb/P15260/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene IFNGR1","url":"https://civicdb.org/features/2888","note":"1 evidence items, 0 assertions, 2 variants; diseases: Melanoma (GraphQL API, CC0)"}],"specificity":"broadly-expressed","distribution":"one-type","specificityNote":"Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA IFNGR1: RNA low tissue specificity; high antibody staining in 14 normal tissues; highest cancer staining head and neck cancer (2 of 4 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas IFNGR1 tissue","url":"https://www.proteinatlas.org/ENSG00000027697-IFNGR1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000027697 associations","url":"https://platform.opentargets.org/target/ENSG00000027697/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:5439","ensembl":"ENSG00000027697","uniprot":"P15260","entrez":"3459","firstDescribed":1988,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Aguet et al, Cell, 1988, \"Molecular cloning and expression of the human interferon-gamma receptor\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2971451/","biology":"Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Associates with transmembrane accessory factor IFNGR2 to form a functional receptor. Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signalling components JAK1 and JAK2. In turn, activated JAK1 phosphorylates IFNGR1 to form a docking site for STAT1. Subsequent phosphorylation of STAT1 leads to dimerisation, translocation to the nucleus, and stimulation of target gene transcription. STAT3 can also be activated in a similar manner although activation seems weaker. Location: Cell membrane (UniProt). Locus 6q23.3 (HGNC).","whereFound":["Melanoma: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/ifngr1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}]}}